Published in Curr Opin Psychiatry on January 01, 2005
Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics. Curr Psychiatry Rep (2007) 0.78
A Genetic Susceptibility Mechanism for Major Depression: Combinations of polymorphisms Defined the Risk of Major Depression and Subpopulations. Medicine (Baltimore) (2015) 0.75
Association between polymorphism of the norepinephrine transporter gene rs2242446 and rs5669 loci and depression disorders. Int J Clin Exp Med (2015) 0.75
Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science (2003) 28.61
Unlocking the potential of the human genome with RNA interference. Nature (2004) 6.70
The RNAi revolution. Nature (2004) 3.96
Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science (2004) 3.65
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol (2003) 3.34
Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry (1998) 3.07
Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry (2003) 2.71
Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science (2004) 2.64
Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem (2003) 2.35
The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci (2003) 2.28
Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry (2004) 2.27
CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther (2004) 1.90
Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression. Biol Psychiatry (2004) 1.85
Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. Mol Psychiatry (2004) 1.76
Antidepressant-induced mania: an overview of current controversies. Bipolar Disord (2003) 1.65
Pharmacogenetics of psychotropic drug response. Am J Psychiatry (2004) 1.61
No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol (2004) 1.55
Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol (2000) 1.51
Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology (2000) 1.45
Serotonin transporter gene polymorphism and antidepressant response. Neuroreport (2000) 1.42
Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. Mol Cell Biol (2003) 1.41
Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry (2002) 1.36
Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol (2000) 1.17
Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry (2004) 1.14
A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett (2004) 1.11
Support of retinal ganglion cell survival and axon regeneration by lithium through a Bcl-2-dependent mechanism. Invest Ophthalmol Vis Sci (2003) 1.11
Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport (2000) 1.06
Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism. Pharmacogenomics J (2003) 1.02
Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry (2004) 1.00
An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther (2003) 0.99
Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. Pharmacol Res (2003) 0.98
The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch Gen Psychiatry (2001) 0.98
Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit (2003) 0.94
Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry (2001) 0.93
Immobilization stress elevates tryptophan hydroxylase mRNA and protein in the rat raphe nuclei. Biol Psychiatry (2004) 0.93
Serotonin transporter 5HTTLPR polymorphism and affective disorders: no evidence of association in a large European multicenter study. Eur J Hum Genet (2004) 0.93
Affective disorders, antidepressant drugs and brain metabolism. Mol Psychiatry (2003) 0.92
Psychopharmacology. FDA weighs suicide risk in children on antidepressants. Science (2004) 0.90
Lithium inhibitable enzymes in postmortem brain of bipolar patients. J Psychiatr Res (2003) 0.89
Atypical depression, atypical temperament and a differential antidepressant response to fluoxetine and nortriptyline. Depress Anxiety (2004) 0.88
Influence of immobilization stress on the levels of CaMKII and phospho-CaMKII in the rat hippocampus. Int J Neuropsychopharmacol (2004) 0.88
D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry (2003) 0.87
High trait anxiety and hyporeactivity to stress of the dorsomedial prefrontal cortex: a combined phMRI and Fos study in rats. Neuroimage (2004) 0.87
From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes. Psychopharmacology (Berl) (2004) 0.85
SSRIs antidepressant activity is influenced by G beta 3 variants. Eur Neuropsychopharmacol (2003) 0.85
Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol (2004) 0.84
Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder. Int J Neuropsychopharmacol (2003) 0.83
Pharmacogenetics in psychosis. Drug News Perspect (2003) 0.82
Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder. Psychopharmacology (Berl) (2004) 0.82
Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J (2001) 0.81
Convergent effects of lithium and valproate on the expression of proteins associated with large dense core vesicles in NGF-differentiated PC12 cells. Neuropsychopharmacology (2004) 0.80
Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet (2004) 0.78
Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders. Pharmacogenomics J (2004) 0.78
Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics. Curr Med Chem (2004) 0.77
Epigenetic studies of genomic retroelements in major psychosis. Schizophr Res (2004) 0.77
Analysis of polymorphisms in the alpha-subunit of the olfactory G-protein Golf in lithium-treated bipolar patients. Psychiatr Genet (2003) 0.77
Long-term responsiveness to lithium as a pharmacogenetic outcome variable: treatment and etiologic implications. Curr Psychiatry Rep (2003) 0.76
Testing the retrovirus hypothesis of manic depression and schizophrenia with molecular genetic techniques. J R Soc Med (1988) 0.76
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA (2009) 6.91
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry (2007) 3.26
High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron (2011) 3.08
Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proc Natl Acad Sci U S A (2007) 2.81
Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet (2004) 2.71
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders. Neurology (2005) 1.93
The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC). Bipolar Disord (2010) 1.90
Phenomenology of rapid-cycling bipolar disorder: data from the first 500 participants in the Systematic Treatment Enhancement Program. Am J Psychiatry (2004) 1.86
Genetic association and brain morphology studies and the chromosome 8p22 pericentriolar material 1 (PCM1) gene in susceptibility to schizophrenia. Arch Gen Psychiatry (2006) 1.86
Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology (2007) 1.70
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry (2002) 1.66
Genetic variation in DTNBP1 influences general cognitive ability. Hum Mol Genet (2006) 1.61
Elucidating the relationship between DISC1, NDEL1 and NDE1 and the risk for schizophrenia: evidence of epistasis and competitive binding. Hum Mol Genet (2008) 1.60
Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry (2002) 1.59
Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability. Am J Psychiatry (2010) 1.58
Interaction between FEZ1 and DISC1 in regulation of neuronal development and risk for schizophrenia. Neuron (2011) 1.57
White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study. Am J Psychiatry (2005) 1.56
Cannabis use disorders in schizophrenia: effects on cognition and symptoms. Schizophr Res (2010) 1.55
Patterns of stress in schizophrenia. Psychiatry Res (2008) 1.55
Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. Am J Psychiatry (2014) 1.50
White matter abnormalities in obsessive-compulsive disorder: a diffusion tensor imaging study. Arch Gen Psychiatry (2005) 1.49
Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry (2003) 1.47
Molecular differentiation of schizoaffective disorder from schizophrenia using BDNF haplotypes. Br J Psychiatry (2009) 1.47
Association of the DTNBP1 locus with schizophrenia in a U.S. population. Am J Hum Genet (2004) 1.45
Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design. J Clin Psychiatry (2015) 1.44
Clinical and cognitive correlates of suicide attempts in bipolar disorder: is suicide predictable? J Clin Psychiatry (2011) 1.42
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry (2006) 1.41
Whither the academic psychiatrist? J Clin Psychiatry (2008) 1.40
Neurocognition as a stable endophenotype in bipolar disorder and schizophrenia. J Nerv Ment Dis (2006) 1.38
Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res (2010) 1.35
D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry (2010) 1.33
High dose D-serine in the treatment of schizophrenia. Schizophr Res (2010) 1.33
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol (2011) 1.31
Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry (2010) 1.29
Impact of childhood abuse on the clinical course of bipolar disorder. Br J Psychiatry (2005) 1.27
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology (2007) 1.27
Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry (2007) 1.26
White matter development in adolescence: diffusion tensor imaging and meta-analytic results. Schizophr Bull (2012) 1.25
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol (2012) 1.25
Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder. Nat Commun (2013) 1.25
Sex differences in frontal lobe white matter microstructure: a DTI study. Neuroreport (2003) 1.23
Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia. Biol Psychiatry (2006) 1.22
Effects of serotonin transporter promoter polymorphisms on serotonin function. Neuropsychopharmacology (2004) 1.21
Antipsychotic drugs and obesity. Trends Mol Med (2010) 1.21
DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia. Biol Psychol (2007) 1.21
A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes. Neuropsychopharmacology (2010) 1.21
DTNBP1 genotype influences cognitive decline in schizophrenia. Schizophr Res (2006) 1.20
DISC1 and neurocognitive function in schizophrenia. Neuroreport (2005) 1.19
Dysbindin genotype and negative symptoms in schizophrenia. Am J Psychiatry (2006) 1.17
Abnormal temporal lobe white matter as a biomarker for genetic risk of bipolar disorder. Biol Psychiatry (2012) 1.16
Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry (2010) 1.16
Assessing cognitive deficits in bipolar disorder: are self-reports valid? Psychiatry Res (2005) 1.16
The MATRICS consensus cognitive battery in patients with bipolar I disorder. Neuropsychopharmacology (2011) 1.15
COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behav Brain Funct (2005) 1.14
Smaller anterior hippocampal formation volume in antipsychotic-naive patients with first-episode schizophrenia. Am J Psychiatry (2003) 1.14
Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology (2011) 1.13
The genetics of symptom-based phenotypes: toward a molecular classification of schizophrenia. Schizophr Bull (2008) 1.11
Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am (2006) 1.10
COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance. Bipolar Disord (2007) 1.08
Implications for health and disease in the genetic signature of the Ashkenazi Jewish population. Genome Biol (2012) 1.08
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry (2003) 1.07
Dimensions of impulsivity and aggression associated with suicide attempts among bipolar patients: a preliminary study. Suicide Life Threat Behav (2004) 1.07
A voxel-based diffusion tensor imaging study of white matter in bipolar disorder. Neuropsychopharmacology (2009) 1.06
Implication of a rare deletion at distal 16p11.2 in schizophrenia. JAMA Psychiatry (2013) 1.05
Resting-state fMRI connectivity impairment in schizophrenia and bipolar disorder. Schizophr Bull (2013) 1.04
Bipolar disorder with comorbid cluster B personality disorder features: impact on suicidality. J Clin Psychiatry (2005) 1.02
In vivo microRNA detection and quantitation in cerebrospinal fluid. J Mol Neurosci (2012) 1.02
Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry (2004) 1.00
The role of COMT Val158Met in cognition. Biol Psychiatry (2008) 0.99
Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol (2009) 0.98
Cognitive dysfunction in bipolar disorder: future place of pharmacotherapy. CNS Drugs (2007) 0.96
Early identification and high-risk strategies for bipolar disorder. Bipolar Disord (2007) 0.95
Transition to mania during treatment of bipolar depression. Neuropsychopharmacology (2010) 0.95
Metabolism and biochemical effects of nicotine for primary care providers. Med Clin North Am (2004) 0.95
Temperament and character dimensions in bipolar I disorder: a comparison to healthy controls. J Psychiatr Res (2008) 0.94
Meta-analysis of genetic variation in DTNBP1 and general cognitive ability. Biol Psychiatry (2010) 0.94
The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry (2002) 0.94
Development and reliability of the HAM-D/MADRS interview: an integrated depression symptom rating scale. Psychiatry Res (2006) 0.94
New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. Int J Epidemiol (2015) 0.93
Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders. Schizophr Bull (2015) 0.93
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenet Genomics (2010) 0.93
Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. Br J Psychiatry (2007) 0.93
Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl) (2004) 0.92
Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci (2009) 0.92
Sex differences in resilience to childhood maltreatment: effects of trauma history on hippocampal volume, general cognition and subclinical psychosis in healthy adults. J Psychiatr Res (2013) 0.91
Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis. Schizophr Bull (2015) 0.91
Levetiracetam for acute mania. Am J Psychiatry (2002) 0.91
Predictors of trait aggression in bipolar disorder. Bipolar Disord (2008) 0.91
Novel multi-nucleotide polymorphisms in the human genome characterized by whole genome and exome sequencing. Nucleic Acids Res (2010) 0.90
The role of general intelligence as an intermediate phenotype for neuropsychiatric disorders. Cogn Neuropsychiatry (2009) 0.90
COMT genotype and manic symptoms in schizophrenia. Schizophr Res (2006) 0.89
Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry (2009) 0.89
DTNBP1 is associated with imaging phenotypes in schizophrenia. Hum Brain Mapp (2009) 0.89
Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry (2007) 0.89